Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 9/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313364 | 0.92 | TYK2 (0.51) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL12012908 | 0.90 | TYK2 (0.49) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL3307930 | 0.89 | TYK2 (0.65) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL3316421 | 0.88 | TYK2 (0.58) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL3310514 | 0.88 | TYK2 (0.51) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL3309765 | 0.86 | TYK2 (0.56) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL11996476 | 0.84 | TTK (0.48) | TYK2STAT3PDE4D | |
| SCHEMBL11996481 | 0.84 | TYK2 (0.49) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL3313948 | 0.84 | TYK2 (0.51) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 | |
| SCHEMBL11996498 | 0.84 | TYK2 (0.50) | TYK2STAT3PDE4DCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | claimed |
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140179674-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2350081-B1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885STAT3 764/4885PDE4D 1445/4885 |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885STAT3 764/4885PDE4D 1445/4885 |
| US-20140179674-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885STAT3 764/4885PDE4D 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.